Reducing tobacco addiction through tobacco product regulation

Tobacco Control

Volumn 13, Issue 2, 2004, Pages 132-135

  Henningfield, J E ^a,b   Benowitz, N L ^c   Connolly, G N ^d   Davis, R M ^e   Gray, N ^f   Myers, M L ^g   Zeller, M ^a  

^a PINNEY ASSOCIATES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g Campaign for Tobacco Free Kids   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

HUMAN; NOTE; PREVALENCE; STANDARDIZATION; TOBACCO DEPENDENCE; WORLD HEALTH ORGANIZATION;

GANGLIONIC STIMULANTS; HUMANS; NICOTINE; PUBLIC HEALTH; TOBACCO INDUSTRY; TOBACCO USE DISORDER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 4143151276     PISSN: 09644563     EISSN: None     Source Type: Journal    
DOI: 10.1136/tc.2003.006890     Document Type: Note

References (46)

1. World Health Organization. Framework Convention on Tobacco Control. Geneva: WHO, 2003. http://www.who.int/tobacco/fctc/text/en/ fctc_en.pdf. 2003.
2. Gray N, Boyle P. The regulation of tobacco and tobacco smoke. Ann Oncol 2000;11:909-14.
3. Gray N, Boyle P. Regulation of cigarette emissions. Ann Oncol 2002;13:19-21.
4. Gray N, Boyle P, Zatonski W. Tar concentrations in cigarettes and carcinogen content. Lancet 1998;352:787-8.
5. Kennedy EM. The need for FDA regulation of tobacco products. Yale Journal of Health Policy, Law and Ethics 2002;III:101-8.
6. Myers ML. Could product regulation result in less hazardous tobacco products? Yale Journal of Health Policy, Law and Ethics 2002;III:139-47.
7. World Health Organization. Advancing knowledge on regulating tobacco products. Geneva: WHO, 2001.
8. Stratton K, Shetty P, Wallace R, Bondurant S, eds. Clearing the smoke: assessing the science base for tobacco harm. Washington DC: National Academy Press, 2001.
9. Parrish SC. Bridging the divide: a shared interest in a coherent national tobacco policy. Yale Journal of Health Policy, Law and Ethics 2002;III:109-18.
10. World Health Organization, Scientific Advisory Committee on Tobacco Product Regulation SACTob. Geneva: WHO, 2003. Recommendation on tobacco product ingredients and emissions, http://www.who.int/tobacco/ sactob/recommendations/ en/ingredients_en.pdf
11. Henningfield JE, Zeller M. Could science-based regulation make tobacco products less addictive? Yale Journal of Health Policy, Law and Ethics 2002;III:127-38.
12. Royal College of Physicians. Nicotine addiction in Britain: a report of the tobacco advisory group of the Royal College of Physicians. London: Royal College of Physicians of London, 2000.
13. Bates C, Jarvis M, Connolly G. Tobacco additives: Cigarette engineering and nicotine addiction. London: Action on Smoking and Health, 1999.
14. Food and Drug Administration. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Federal Register 1995;60:41314-792.
15. Food and Drug Administration. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Federal Register 1996;61:44396-5318.
16. Hurt RD, Robertson CR. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA 1998;280:1173-81.
17. Slade J, Bero LA, Hanauer P, et al. Nicotine and addiction. The Brown and Williamson documents. JAMA 1995;274:225-33.
18. US Department of Health and Human Services. The health consequences of smoking: nicotine addiction, A report of the Surgeon General, 1988. Rockville, Maryland: Public Health Service, Centers for Disease Control, Office on Smoking and Health, 1988. (DHHS Publication No (CDC) 88-8406.)
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Association, 1994.
20. Schuster CR, Henningfield J. Conference on abuse liability assessment of CNS drugs. Drug and Alcohol Dependence 2003;70:S1-4.
21. Bachman JG, O'Malley PM, Schulenberg JE, et al. The decline of substance use in young adulthood: changes in social activities, roles, and beliefs. Mahawah, New Jersey: Lawrence Erlbaum Associates, 2002.
22. Hertz S. Presentation to the FDA Anesthetic and Life Support Drugs Advisory Committee, September 10, 2003. 2003. Bethesda, Maryland: FDA Dockets, 2003. Transcripts.
23. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 1994;331:123-5.
24. World Health Organization, Scientific Advisory Committee on Tobacco Product Regulation SACTob. Recommendation on nicotine and the regulation in tobacco and non-tobacco products. http://www.who.int/tobacco/sactob/ recommendations/en/nicotine_en.pdf, 2002.
25. Henningfield JE, Benowitz NL, Slade J, et al. Reducing the addictiveness of cigarettes. Tobacco Control 1998;7:281-93.
26. Bates C, McNeill A, Jarvis MJ, et al. The future of tobacco product regulation and labeling in Europe: implications for the forthcoming European Union directive. Tobacco Control 1999;8:225-35.
27. Gray N, Boyle P. The future of the nicotine-addiction market. Lancet 2003;362:845-0.
28. Novotny TE, Cohen JC, Yurekli A, et al. Smoking cessation and nicotine-replacement therapies. In Jha P, Chaloupka FJ, eds. Tobacco control in developing countries, 287-307. Oxford: Oxford University Press, 2000.
29. Warner KE, Peck CC, Woosley RL, et al. Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food and Drug Law Journal 1998;53(suppl):1-8.
30. Henningfield JE, Moolchan ET, Zeller M. Regulatory strategies to reduce tobacco addiction in youth. Tobacco Control 2003;12(suppl I):i14-24.
31. Committee on Opportunities in Drug Abuse, Research Division of Neuroscience and Behavioral Healtn, Institute of Medicine. Pathways of addiction: opportunities in drug abuse research. Washington DC: National Academy Press, 1996.
32. Expert Panel, (Henningfield JE, Johanson CE Sellers EM, rapporteurs). Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Dependence 2003;70:S107-14.
33. O'Brien CP. Drug addiction and drug abuse. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996:557-77.
34. Henningfield JE, Kozlowski LT, Benowitz NL. A proposal to develop meaningful labeling for cigarettes. JAMA 1994;272:312-4.
35. National Cancer Institute. Risks associated with smoking cigarettes with low-machine measured yields of tar and nicotine. Smoking and Tobacco Control Monograph No. 13. Bethesda, Maryland: US Department of Health and Human Services, National Institutes of Health, National Cancer Institutes, 2002. (NIH Publication No. 02-5074.)
36. Ingebrethsen BJ. Deposition provided in litigation brought on behalf of "The People of the State of California, et al. versus Philip Morris, Inc. et al." March 24 and 25, 1998.
37. Holmes JC, Seligman RB, and Philip Morris, Inc. Idea No. 99-Means of controlling particle size of cigarette smoke and of incorporating volatile flavors. American Legacy Foundation Tobacco Documents website. Bates No.2021627703, 2021627706. 1957.
38. Douglas CE. Taking aim at the bull's eye: the nicotine in tobacco products. Tobacco Control 1998;7:215-8.
39. Kessler D. A question of intent: a great American battle with a deadly industry. New York, NY: Public Affairs, 2001.
40. Henningfield JE, Fant RV, Gitchell J, et al. Tobacco dependence. Global public health potential for new medications development and indications. Ann NY Acad Sci 2000;909:247-56.
41. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug and Alcohol Dependence 2003;70:S13-40.
42. Slade J, Henningfield JE. Tobacco product regulation: context and issues. Food and Drug Law Journal 1998;53:43-74.
43. Houtsmuller EJ, Fant RV, Eissenberg TE, et al. Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacology, Biochemistry and Behavior 2002;72:559-68.
44. Warner KE, Slade J, Sweanor DT. The emerging market for long-term nicotine maintenance. JAMA 1997;278:1087-92.
45. Henningfield JE, Slade J. Tobacco dependence medications: public health and regulatory issues. Food and Drug Law Journal 1998;53:75-114.
46. Schuh KJ, Schuh LM, Henningfield JE, et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology (Berl) 1997;130:352-61.